These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Re: Hemorrhages during escitalopram-venlafaxine-mirtazapine combination treatment of depression. Al-Adwani A Can J Psychiatry; 2005 Nov; 50(13):877; author reply 877-8. PubMed ID: 16483124 [No Abstract] [Full Text] [Related]
12. Photodistributed eruptive telangiectasia: an uncommon adverse drug reaction to venlafaxine. Vaccaro M; Borgia F; Barbuzza O; Guarneri B Br J Dermatol; 2007 Oct; 157(4):822-4. PubMed ID: 17655739 [No Abstract] [Full Text] [Related]
13. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. Kennedy SH; Andersen HF; Lam RW J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428 [TBL] [Abstract][Full Text] [Related]
15. Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression. Leonard B; Taylor D J Psychopharmacol; 2010 Aug; 24(8):1143-52. PubMed ID: 20147575 [TBL] [Abstract][Full Text] [Related]
16. Escitalopram: a review of its use in the management of major depressive disorder in adults. Garnock-Jones KP; McCormack PL CNS Drugs; 2010 Sep; 24(9):769-96. PubMed ID: 20806989 [TBL] [Abstract][Full Text] [Related]
17. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. Lam RW; Lönn SL; Despiégel N Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of escitalopram in major depressive disorder in the Dutch health care setting. Nuijten MJ; Brignone M; Marteau F; den Boer JA; Hoencamp E Clin Ther; 2012 Jun; 34(6):1364-78. PubMed ID: 22578310 [TBL] [Abstract][Full Text] [Related]
20. Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. Yrondi A; Fiori LM; Frey BN; Lam RW; MacQueen GM; Milev R; Müller DJ; Foster JA; Kennedy SH; Turecki G Int J Neuropsychopharmacol; 2020 Feb; 23(2):88-95. PubMed ID: 31819986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]